MG Biologics

MG Biologics is a private veterinary biologics company founded in 2012 (with roots dating to 1999) and headquartered in Ames, Iowa. It operates a commercial-stage business model, manufacturing and selling a portfolio of hyperimmune plasma and antibody products for livestock and companion animals, with key offerings for Clostridium perfringens, tetanus, Rhodococcus equi, and snake envenomation. The company leverages a donor herd platform to produce targeted antibody therapies, emphasizing custom blends and research-backed formulations to reduce disease severity in animals.

Hyperimmune plasma and polyclonal antibody production platform utilizing vaccinated donor animal herds (equine, etc.). The platform involves immunizing donors against specific pathogens, collecting high-titer plasma, and processing it into therapeutic products for passive immunization in target species.

Operates in the veterinary hyperimmune plasma and antibody segment, competing against other specialty plasma manufacturers and larger diversified animal health companies (e.g., Zoetis, Merck Animal Health). Differentiation is achieved through customer service, custom formulation capabilities, and a specific focus on equine neonatal health and a unique antivenom product.